A protocol for a randomized trial evaluating the role of carbon‐ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma
Cancer Medicine · 2024
DOI: 10.1002/cam4.6742 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jiyi Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Heavy Ion Radiotherapy, Nasopharyngeal Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Health Commission Clinical research project, the Key research and development Program of the Ministry of Science and Technology, the Science and Technology Development Fund of Shanghai Pudong New Area.
Abstract (Originalsprache)
Purpose
Management of locoregionally recurrent nasopharyngeal carcinoma (LR NPC) is difficult. Although carbon‐ion radiation therapy (CIRT) could substantially improve the overall survival (OS) of those patients, around 40% of the patients may still develop local failure. Further improvement of the disease control is necessary. Immunotherapy, such as immune checkpoint inhibitors (ICIs) becomes a promising antitumor treatment. The role of ICIs was proved in head and neck cancers including recurrent/metastatic NPC. Preclinical studies indicated potential synergistic effects between radiation therapy and ICIs. Therefore, we conduct a randomized phase 2 trial to evaluate the efficacy and safety of camrelizumab, an anti‐PD‐1 monoclonal antibody, along with CIRT in patients with LR NPC.
Methods
Patients will be randomly assigned at 1:1 to receive either standard CIRT with 63 Gy (relatively biological effectiveness, [RBE]) in 21 fractions, or standard CIRT plus concurrent camrelizumab. Camrelizumab will be administered intravenously with a dose of 200 mg, every 2 week, for a maximum of 1 year. We estimate addition of camrelizumab will improve the 2‐year progression‐free survival (PFS) from 45% to 60%. A total of 146 patients (with a 5% lost to follow‐up rate) is required to yield a type I error of 0.2, and a power of 0.8. Results and Conclusion The results of the trial may shed insights on the combined therapy with ICIs and CIRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China.
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China.
- Shanghai Key Laboratory of radiation oncology, Shanghai, China.
- Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China.
- Department of Radiation Oncology, Proton and Heavy Ion Center, Heyou International Hospital, Foshan, China.
ORCID-Profile: Qingting Huang
Förderung
- Shanghai Municipal Health Commission Clinical research project
- the Key research and development Program of the Ministry of Science and Technology
- the Science and Technology Development Fund of Shanghai Pudong New Area
Zitieren
APA
Hu, J., Huang, Q., Hu, W., Gao, J., Yang, J., Zhang, H., Lu, J. J., & Kong, L. (2024). A protocol for a randomized trial evaluating the role of carbon‐ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.6742
Vancouver
Hu J, Huang Q, Hu W, Gao J, Yang J, Zhang H, et al. A protocol for a randomized trial evaluating the role of carbon‐ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma. Cancer Medicine. 2024. doi:10.1002/cam4.6742
BibTeX
@article{Hu2024,
author = {Hu, Jiyi and Huang, Qingting and Hu, Weixu and Gao, Jing and Yang, Jing and Zhang, Haojiong and Lu, Jiade Jay and Kong, Lin},
title = {A protocol for a randomized trial evaluating the role of carbon‐ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.6742}
}
EUVIMED